LNLuisa Macambira Noronha

Luisa Macambira Noronha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luisa Macambira Noronha has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COVID-19 in China, Italy and the United States of America: a short review

    by Amanda Ribeiro Rangel, Luísa Macambira Noronha, Gabriel Cavalcante Lima Chagas, Gdayllon Cavalcante Meneses, Geraldo Bezerra da Silva Júnior, Roberto da Justa Pires Neto, Elizabeth De Francesco Daher

    In December 2019, a novel coronavirus was discovered and associated with a cluster of pneumonia of unknown cause in China. SARS-CoV-2 rapidly spread and is now characterized as a pandemic. The objective of this study is to discuss COVID-19 general features, including epidemiology, transmission, control measures, virology, diagnosis, clinical characteristics and radiological and laboratory results. In this context, literature was assessed to compare the three most affected countries in Asia, Europe and Americas on March 31, 2020. The main form of transmission is human-to-human by respiratory secretions, and studies indicated substantial involvement of asymptomatic patients in this process. COVID-19 patients are predominantly men and may present multiple symptoms, especially fever and cough. Arterial hypertension and diabetes mellitus were the most common comorbidities. Worse outcomes are associated with increased age, comorbidities, and complications. Abnormalities in computed tomography of the chest are frequent, with pulmonary ground-glass opacity and bilateral patchy shadowing as the most common patterns, but a significant percentage of patients do not present any findings at time of admission. Laboratory results often present lymphocytopenia, increased neutrophils and platelet counts, erythrocyte sedimentation rate, lactate dehydrogenase, C-reactive protein, ferritin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine, creatine phosphokinase, myoglobin, glucose and cytokines. Although radiological findings and laboratory results presented similarities in China, Italy and USA, case-fatality rates can be conflicting suggesting, therefore, the need for studies according to each region.


  • Open Access

    COVID-19 and Kidney: a narrative review

    by Gabriel Cavalcante Lima Chagas, Amanda Ribeiro Rangel, Luisa Macambira Noronha, Geraldo Bezerra da Silva Jr., Gdayllon Cavalcante Meneses, Alice Maria Costa Martins, Elizabeth De Francesco Daher

    COVID-19 is a pandemic associated with systemic clinical manifestations. In this study, we aimed to present a narrative review on kidney involvement in COVID-19. Kidney involvement could be derived from direct cytopathic effects, immunological mechanisms, indirect effects on renal tissue through other mediators, and dysfunction or injury of other organs. The evolution of COVID-19 may be complicated with acute kidney injury (AKI) in a significant percentage of patients, and renal dysfunction seems to be associated with worse prognosis. Patients with chronic kidney disease (CKD) seem to be more susceptible to the severe forms of COVID-19. Patients with renal replacement therapy (RRT) are also a vulnerable population as consequence of their advanced age, underlying comorbidities, impaired immune response, and clustering in hemodialysis centers, with requirements for frequent contact with healthcare services. Kidney transplant patients may be at high-risk due to long-term immunosuppression and comorbidities, hence, managing immunosuppression is imperative. Lastly, renal replacement therapy may be required during COVID-19, and different modalities are discussed based on clinical findings and laboratorial aspects. Therefore, COVID-19 seems to affect kidney by different mechanisms, which contributes for AKI development and increases the severity of the disease. Also, patients with CKD and kidney transplant recipients are at higher risk for COVID-19 and mortality.